Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

This publication has 25 references indexed in Scilit:

• Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
  Journal of Clinical Oncology, 2005
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
  Journal of Clinical Oncology, 2005
• A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
  New England Journal of Medicine, 2004
• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
  New England Journal of Medicine, 2003
• Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
  Journal of Clinical Oncology, 2003
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002
• Five Years of Tamoxifen--or More?
  JNCI Journal of the National Cancer Institute, 1996
• Asymptotically Efficient Rank Invariant Test Procedures
  Journal of the Royal Statistical Society. Series A (General), 1972
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958